Esperion Therapeutics (ESPR) Upgraded by BidaskClub to “Buy”

Share on StockTwits

BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research note released on Friday.

Other research analysts have also recently issued research reports about the company. Cowen reiterated a buy rating and set a $95.00 price objective on shares of Esperion Therapeutics in a research report on Monday, August 6th. Zacks Investment Research upgraded Esperion Therapeutics from a hold rating to a buy rating and set a $48.00 price objective on the stock in a research report on Tuesday, July 31st. BTIG Research started coverage on Esperion Therapeutics in a research report on Tuesday. They set a buy rating and a $82.00 price objective on the stock. Stifel Nicolaus started coverage on Esperion Therapeutics in a research report on Friday, September 14th. They set a buy rating and a $89.00 price objective on the stock. Finally, Citigroup upgraded Esperion Therapeutics from a neutral rating to a buy rating and increased their price objective for the stock from $57.00 to $75.00 in a research report on Friday, August 17th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics has an average rating of Buy and an average target price of $80.89.

ESPR traded down $3.27 during trading hours on Friday, reaching $44.98. The company’s stock had a trading volume of 606,245 shares, compared to its average volume of 586,413. Esperion Therapeutics has a 52 week low of $33.06 and a 52 week high of $82.68. The stock has a market cap of $1.29 billion, a PE ratio of -6.44 and a beta of 2.23.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.01). During the same quarter last year, the company posted ($1.92) earnings per share. Analysts predict that Esperion Therapeutics will post -6.31 earnings per share for the current year.

In related news, Director Roger S. Newton sold 7,300 shares of the firm’s stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $50.06, for a total value of $365,438.00. Following the sale, the director now directly owns 616,426 shares of the company’s stock, valued at $30,858,285.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Roger S. Newton sold 9,400 shares of the firm’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $50.01, for a total value of $470,094.00. Following the completion of the sale, the director now directly owns 589,326 shares in the company, valued at $29,472,193.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,500 shares of company stock worth $1,744,117. 32.50% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB acquired a new stake in Esperion Therapeutics in the first quarter valued at about $250,000. Keybank National Association OH boosted its stake in shares of Esperion Therapeutics by 97.7% during the second quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 3,787 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Esperion Therapeutics by 40.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 2,224 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Esperion Therapeutics during the second quarter valued at about $333,000. Finally, BTG Pactual Global Asset Management Ltd boosted its stake in shares of Esperion Therapeutics by 20.2% during the second quarter. BTG Pactual Global Asset Management Ltd now owns 8,719 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 1,465 shares in the last quarter.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

First of Long Island Corp  Director Acquires $19,590.00 in Stock
First of Long Island Corp Director Acquires $19,590.00 in Stock
Fifth Third Bancorp Buys 4,250 Shares of Jack in the Box Inc.
Fifth Third Bancorp Buys 4,250 Shares of Jack in the Box Inc.
Fifth Third Bancorp Has $11.33 Million Holdings in Waste Management, Inc.
Fifth Third Bancorp Has $11.33 Million Holdings in Waste Management, Inc.
Dynamic Technology Lab Private Ltd Acquires New Position in Carlisle Companies, Inc.
Dynamic Technology Lab Private Ltd Acquires New Position in Carlisle Companies, Inc.
Dynamic Technology Lab Private Ltd Takes $973,000 Position in ViaSat, Inc.
Dynamic Technology Lab Private Ltd Takes $973,000 Position in ViaSat, Inc.
Dynamic Technology Lab Private Ltd Sells 8,625 Shares of TreeHouse Foods Inc.
Dynamic Technology Lab Private Ltd Sells 8,625 Shares of TreeHouse Foods Inc.


© 2006-2018 Ticker Report